review Open AccessTop 1% cited

Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination

Drugs · 2013 · Vol. 73(2) · pp. 159–177

George G. Zhanel✉(University of Manitoba)Christopher D. Lawson(University of Manitoba)Heather J. Adam(Health Sciences Centre)Frank Schweizer(University of Manitoba)Sheryl Zelenitsky(University of Manitoba)Philippe Lagacé‐Wiens(University of Manitoba)Andrew Denisuik(University of Manitoba)Ethan Rubinstein(University of Manitoba)Alfred S. Gin(Health Sciences Centre)Daryl J. Hoban(University of Manitoba)Joseph P. Lynch(Olive View-UCLA Medical Center)James A. Karlowsky(University of Manitoba)

View via DOI Publisher page

Antibiotic Resistance in Bacteria Antibiotics Pharmacokinetics and Efficacy Pneumonia and Respiratory InfectionsAvibactamCeftazidimeCeftazidime/avibactamBeta-Lactamase InhibitorsMedicinePharmacokineticsPharmacologyMicrobiologyCephalosporinChemistry

MeSH terms

Anti-Bacterial AgentsBacterial InfectionsCeftazidimeClinical Trials as TopicDrug Therapy, CombinationHumansMicrobial Sensitivity TestsAzabicyclo Compoundsbeta-Lactamase Inhibitors

Citations

419

FWCI

13.54

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli